Cholesterol levels remain higher than recommended levels despite widespread education and greater availability of cholesterol-lowering medicines, according to researchers at the University of Rochester Medical Center, New York.
Cholesterol levels remain higher than recommended levels despite widespread education and greater availability of cholesterol-lowering medicines, according to researchers at the University of Rochester Medical Center, New York.
Thomas Pearson, professor and chair of the school's department of community and preventive medicine, and his colleagues surveyed 619 primary care physicians who were most likely to prescribe cholesterol-lowering products. Of the physicians' 5,601 patients who were undergoing treatment for high cholesterol, only 38% had low-density lipoprotein levels within the ranges recommended by the National Institutes of Health's National Cholesterol Education Program.
The researchers also discovered that successful treatment rates decreased as a patient's risk factors increased. Among patients with fewer than two risk factors for cardiovascular disease, 68% reached the recommended level of 160 mg/dL; among those with two or more risk factors, only 37% reached their goal; and among patients with coronary heart disease, a mere 18% reached the recommended level of 100 mg/dL.
"Many patients don't change their diet or get more exercise even when prompted by their physicians," said Pearson. "Sometimes doctors start a [patient on a] medication and then call a patient 'treated' even though the first dose may not be enough."
The study, which was funded by Parke-Davis and Pfizer Inc., also revealed discrepancies in cholesterol-lowering success rates along racial lines. While 18% of white patients with coronary heart disease and 21% of Hispanic patients with coronary heart disease met their target goals, their African American counterparts had only a 5% success rate.
Patients who had the greatest success rates were those who followed their physician's advice to exercise more or change their diet to include less saturated fat. PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
MDMA Therapy for Mental Health Conditions: Do the Benefits Outweigh the Risks?
October 25th 2024Despite a recent FDA Complete Response Letter issued to Lykos for midomafetamine capsules for the treatment of post-traumatic stress disorder, experts believe that the future is bright for psychedelic drugs that treat mental health conditions.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.